

13 February 2020



Ref: H202000044

Dear 

Response to your request for official information.

Thank you for your request of 8 January 2019 under the Official Information Act 1982 (the Act) to the Ministry of Health (the Ministry) for:

"I request your information on the four following linked topics: The first three are essentially synonyms for the condition and the fourth is a drug which is effective in slowing progression. I can send you references from the medical literature if that would help. amyloid/amyloidosis/ATTRwt/tafamidis"

The Ministry does not hold information relating to specific conditions including amyloid/amyloidosis/ATTRwt. This part of your request is therefore refused under section 18(g) of the Act as the information is not held by the Ministry.

Tafamidis is an active ingredient in the medicine Vyndaqel. Vyndaqel is not an approved medicine in New Zealand or Australia as no company has put in an application, although it is being supplied via section 29 of the Medicines Act 1981. As such, a patient can discuss whether Vyndaqel is a viable treatment option with their doctor. In these cases, the doctor must take the responsibility for both the safety and quality of the product as well.

I trust this information fulfils your request. Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any decisions made in this response.

Please note that this response, with your personal details removed, may be published on the Ministry website.

Yours sincerely

A handwritten signature in blue ink, appearing to read 'Chris James'.

Chris James
Group Manager
Medsafe